Skip to content

PITALC. Pilot study on the effect of PITAC (Pressurized IntraThoracic Aerosol Chemotherapy) by videothoracoscopy in patients with malignant pleural effusion in the light of the results of a retrospective historical cohort treated with talc pleurodesis by videothoracoscopy

Status
Not yet recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-523482-23-00
Enrollment
20
Registered
2026-07-16
Start date
Unknown
Completion date
Unknown
Last updated
2026-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neoplastic pleural effusion

Brief summary

the percentage of recurrence of pleural effusion assessed at 1 month by chest X-ray. Recurrence of pleural effusion is defined by a higher ipsilateral pleural effusion at 1 month compared to hospitalization discharge.

Detailed description

Percentage of patients for whom PITAC is fully completed, percentage of patients for whom PITAC is partially completed and percentage of patients for whom PITAC is finally not performed., Overall survival, defined as the delay between PITAC and death. Patients alive at the last assessment will be censored. Estimate will be given at 12 months, Adverse events with assessment at each 12-month follow-up period: renal, hepatic or hematological toxicity, lung injury, acute respiratory distress syndrome, prolonged air leak, hemothorax, wound reopening, pulmonary hernia and toxic emphysema. An independent data safety monitoring board (DSMB) will monitor the safety of the study and make recommendations regarding its continuation, Assessment of quality of life using the EORTC QLQ-C30 questionnaire at 1 and 3 months., Assessment of dyspnea using the MMRC scale at 1, 3, 6 and 12 months., Postoperative complications according to Clavien classification at 3 months., Percentage of patients with local disease control according to chest CT scan at 3 months. The local disease progression at 3 months is assessed by pleural effusion (more significant) and/or the appearance or progression of pleural nodules (number or volume) compared to inclusion., Percentage of recurrence of pleural effusion and mean change of maximum diameter of the pleural effusion assessed at 1 month by pleural ultrasound. Recurrence of pleural effusion is defined by a higher ipsilateral pleural effusion at 1 month compared to hospitalization discharge., Ancillary endpoint: Same endpoints as those used for the assessment of the PITAC strategy (see criteria above).

Interventions

DRUGsolution pour perfusion
DRUGsolution à diluer pour perfusion

Sponsors

Hospices Civils De Lyon
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
the percentage of recurrence of pleural effusion assessed at 1 month by chest X-ray. Recurrence of pleural effusion is defined by a higher ipsilateral pleural effusion at 1 month compared to hospitalization discharge.

Secondary

MeasureTime frame
Percentage of patients for whom PITAC is fully completed, percentage of patients for whom PITAC is partially completed and percentage of patients for whom PITAC is finally not performed., Overall survival, defined as the delay between PITAC and death. Patients alive at the last assessment will be censored. Estimate will be given at 12 months, Adverse events with assessment at each 12-month follow-up period: renal, hepatic or hematological toxicity, lung injury, acute respiratory distress syndrome, prolonged air leak, hemothorax, wound reopening, pulmonary hernia and toxic emphysema. An independent data safety monitoring board (DSMB) will monitor the safety of the study and make recommendations regarding its continuation, Assessment of quality of life using the EORTC QLQ-C30 questionnaire at 1 and 3 months., Assessment of dyspnea using the MMRC scale at 1, 3, 6 and 12 months., Postoperative complications according to Clavien classification at 3 months., Percentage of patients with local

Outcome results

None listed

Source: EU CTIS · Data processed: Jul 17, 2026